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Acute kidney injury (AKI) has emerged as a major public
health problem that affects millions of patients worldwide
and leads to decreased survival and increased progression of
underlying chronic kidney disease (CKD). Recent consensus
criteria for definition and classification of AKI have provided
more consistent estimates of AKI epidemiology. Patients,
in particular those in the ICU, are dying of AKI and not just
simply with AKI. Even small changes in serum creatinine
concentrations are associated with a substantial increase in
the risk of death. AKI is not a single disease but rather a
syndrome comprising multiple clinical conditions. Outcomes
from AKI depend on the underlying disease, the severity and
duration of renal impairment, and the patient’s renal baseline
condition. The development of AKI is the consequence
of complex interactions between the actual insult and
subsequent activation of inflammation and coagulation.
Contrary to the conventional view, recent experimental and
clinical data argue against renal ischemia–reperfusion as
a sine qua non condition for the development of AKI.
Loss of renal function can occur without histological signs
of tubular damage or even necrosis. The detrimental effects
of AKI are not limited to classical well-known symptoms such
as fluid overload and electrolyte abnormalities. AKI can also
lead to problems that are not readily appreciated at the
bedside and can extend well beyond the ICU stay, including
progression of CKD and impaired innate immunity.
Experimental and small observational studies provide
evidence that AKI impairs (innate) immunity and is associated
with higher infection rates.
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Acute kidney injury (AKI) is now recognized as a major
public health problem affecting millions of patients world-
wide and leading to decreased survival, increased progression
of underlying chronic kidney disease (CKD), and sometimes
to new onset of CKD. Recent consensus criteria for definition
and classification of AKI have allowed for more consistent
estimates of epidemiology and have now led to the first
clinical practice guideline for AKI.1 However, questions
remain in terms of which patients are at highest risk for AKI
and for adverse outcomes. Furthermore, AKI is not a single
disease but rather a syndrome comprising multiple clinical
conditions. Outcomes in AKI are influenced by the under-
lying disease causing the condition, as well as by the severity
and duration of renal impairment and by the baseline
condition of the patient. In whom does AKI result in these
outcomes is also the subject of active research and much
speculation. This review will briefly outline the currently
accepted definition and classification criteria for AKI, the
epidemiology of AKI based on these criteria, and the
outcomes of AKI reported in the literature. We will then
examine what is known concerning the pathogenesis of AKI
as relates to the clinical epidemiology and risk stratification
and also explore new concepts in the pathophysiology of AKI
so as to better understand how AKI results in the outcomes
for which it is associated.
DEFINITION, CLASSIFICATION, AND STANDARDIZATION
OF AKI
Research in acute renal failure has long been hampered by a
lack of standardization in classification. At one time, more
than 35 different definitions of acute renal failure were being
used in the literature.2 Depending on the definition, acute
renal failure was said to affect anywhere from 1 to 25% of
intensive care unit (ICU) patients and to carry a mortality
rate from 15 to 60%.3–5 Such variation limits the ability to
compare studies, to standardize study protocols, or even to
communicate effectively across research groups.
As a consequence of the confusion surrounding the
definition of acute renal failure, demands for a consensus
definition and a classification system for acute renal failure
have emerged.6,7 Following long advocacy and persistent
work, such a system, the RIFLE system (Figure 1), was
ultimately developed, involving a broad consensus of
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experts.7 The acronym RIFLE represents the increasing
severity classes Risk, Injury, and Failure and the two outcome
classes Loss and End-Stage Kidney Disease. The severity
grades R–F are defined on the basis of changes in serum
creatinine or urine output, wherein the worst of each
criterion is used. The two outcome criteria, L and E, are
defined by the duration of loss of kidney function.
Moreover, the term AKI is intended to encompass the
entire spectrum of the syndrome, from minor impairment in
renal function to the need for renal replacement therapy.8
AKI is more than just acute renal failure; it encompasses
the entire spectrum from severe to less severe conditions.
Thereby, the focus is not exclusively on patients with renal
failure or on those who receive dialysis, but attention is
also paid to the strong association of AKI with hospital
mortality even when only a minority of patients receive renal
replacement therapy.9
The AKI Network, a somewhat larger, multidisciplinary,
international group, subsequently proposed some small
modifications to the RIFLE criteria (Figure 1):8 (1) broad-
ening of the ‘Risk’ category of RIFLE to include an increase
in serum creatinine of at least 0.3mg/dl, even if this does not
reach the 50% threshold; (2) setting a 48-h window on the
first documentation of any criteria; and (3) categorizing
patients as ‘Failure’ if they are treated with renal replacement
therapy regardless of what their serum creatinine or urine
output is at the point of initiation (Figure 1). Broadening
the criteria for ‘Risk’ (Stage 1) has led to increased sensitivity
(more individuals are classified as having AKI). This differ-
ence, however, affects only 1–2% of patients. Studies validat-
ing RIFLE/AKI Network criteria have now included more
than 500,000 patients.
EPIDEMIOLOGY
Using RIFLE criteria, investigators from around the world
have shown that AKI is common and results in a substantial
increase in hospital mortality. Uchino et al.5 assessed the
predictive ability of the RIFLE classification in a cohort of
20,126 patients admitted to a teaching hospital for 424 h
over a 3-year period. Approximately 10% of the patients
achieved a maximum RIFLE-R, 5% I and 3.5% F. The authors
also found a nearly linear increase in hospital mortality with
increasing RIFLE class, with patients at R having more than
three times the mortality rate of patients without AKI. R
carried an odds ratio of hospital mortality of 2.5, I of 5.4, and
F of 10.1.
The occurrence of AKI in the ICU was studied in 120,123
patients admitted to one of 57 intensive care units across
Australia from January 2000 to December 2005.10 Here, AKI
occurred in 36.1%, with a maximum category R in 16.3%, I
in 13.6%, and F in 6.3%. AKI was associated with an increase
in hospital mortality (odds ratio 3.29; 95% confidence
interval 3.19–3.41; Po0.0001). The crude hospital mortality
was 17.9% for R, 27.7% for I, and 33.2% for F. After
multivariable analysis, each RIFLE category was indepen-
dently associated with hospital mortality (odds ratio: R 1.58,
I 2.54, and F 3.22). However, this study was limited to AKI
that occurred on or before the first day of ICU care and
therefore primarily represents community-acquired AKI.
Hoste et al.9 found that AKI occurred in two-thirds of
ICU patients, whereas RIFLE criteria were fulfilled at ICU
admission in only 22% of patients. In multivariable analysis,
AKI (hazard ratio 1.7; 95% confidence interval 1.28–2.13;
Po0.001) and maximum RIFLE classes ‘Injury’ (hazard
ratio 1.4; 95% confidence interval 1.02–1.88; P¼ 0.037) and
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Figure 1 |Direct comparison of RIFLE (Risk of renal dysfunction, Injury to the kidney, Failure or Loss of kidney function, and
End-stage kidney disease) and Acute Kidney Injury (AKI) Network criteria to classify AKI according to Bellomo et al.7 and Mehta
et al.,8 respectively. Note that the original RIFLE criteria also listed glomerular filtration rates as reference, but these do not precisely agree
with the changes in serum creatinine and were subsequently removed. For AKI Network criteria, the change in serum creatinine from
baseline follows RIFLE, but there is also the option to use a 0.3mg/dl increase if it is observed to occur within a 48-h period.
RRT, renal replacement therapy.
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‘Failure’ (hazard ratio 2.7; 95% confidence interval 2.03–3.55;
Po0.001) were associated with hospital mortality after
adjusting for multiple covariates.
Finally, Ali et al.11 studied the incidence of AKI in the
population of northern Scotland, a geographical population
base of 523,390. The incidence of AKI was 2147 per million
population. Sepsis was a precipitating factor in 47% of
patients. RIFLE classification was useful for predicting
recovery of renal function (Po0.001), requirement for renal
replacement therapy (Po0.001), length of hospital stay for
survivors (Po0.001), and in-hospital mortality (P¼ 0.035).
Thus, AKI is strongly associated with hospital mortality and
resource use and remains so even after adjusting for baseline
severity of illness, case mix, race, gender, and age.
ETIOLOGY AND RISK ASSESSMENT
Given how common AKI is and how significant its impact on
survival is, one might expect more detailed information to be
available on its cause. However, until recently, there have
been two major obstacles to obtaining robust assessments of
etiology and therefore it has been difficult to properly
characterize risk for AKI. First, the lack of standard criteria
for diagnosis of AKI has meant that observational studies
cannot easily be compared to determine what demographic
variables are associated with a general risk of AKI as against
those that are specific to the underlying condition that leads
to an exposure known to produce AKI. For example, risk
factors for AKI in the setting of cardiac surgery tend to
confound risks of AKI with risks for cardiovascular disease.
A related problem comes from the observation that CKD
puts patients at risk for AKI.12,13 In most epidemiological
studies it has not been possible to separate susceptibility for
AKI from risk factors for CKD. In a study of 5383 critically
ill patients, gender and race were not found to alter AKI
susceptibility, whereas age was a consistent risk factor.9
Interestingly, surgical admissions were at greater risk than
medical and ICU admissions for cardiovascular, neuro-
logical, and respiratory disease/infection, whereas those for
trauma, malignancy, and other causes were at decreased
risk. Similarly, we reported recently on 1836 patients hospi-
talized for community-acquired pneumonia.14 In this study,
one-third (34%) of the patients developed AKI. Baseline
susceptibilities for AKI in this setting included age, white
race, and baseline comorbidities such as CKD, cardiac
disease, and diabetes.
However, risk for disease represents the interaction
between susceptibility (i.e., features intrinsic to the patient)
and exposure (i.e., the causative factor or factors). Exposures
known to produce AKI in susceptible populations include
sepsis, ischemia, heart failure, liver disease, major surgery
(especially vascular and cardiac), myonecrosis, urinary
tract obstruction, and various nephrotoxins.5 In the critically
ill, sepsis is the major cause of AKI, accounting for nearly
50% of cases.5,11,15 Several studies have reported that sepsis-
induced AKI is associated with short- and long-term risk
of death.10,14
The second obstacle to establishing accurate information
on causes of AKI and therefore on risk assessment is that
we continue to have an incomplete understanding of the
pathogenesis of AKI in many of the circumstances in which
it is seen. Although there are many reasons for this, we and
others have argued that the lack of suitable animal models is
a major factor.16,17 Thus, for AKI occurring in many
common settings (e.g., sepsis, cardiac surgery, radio con-
trast), a better understanding of pathogenesis is needed.
OUTCOMES AND PATHOPHYSIOLOGY
There is now substantial evidence from clinical studies that
both short-term and long-term outcomes are adversely
affected by AKI (Figure 2). As discussed above, hospital
mortality increases in association with AKI stage. Further-
more, survival appears to be affected for at least 1 year and
maybe longer.14 In addition to survival, the development of
sepsis appears to be common in patients with AKI and is
associated with high mortality and increased hospital
duration.18
Recovery of renal function is also a problem, with many
patients failing to recover renal function. Chertow et al.19
demonstrated in a cohort of critically ill patients with
AKI who required renal replacement therapy that 33% of
the survivors were still on renal replacement therapy after
12 months. The Acute Renal Failure Trials Network study
enrolled 1124 patients with severe AKI, and nearly 25% of the
survivors were dependent on renal replacement therapy on
day 60.20 However, an Australian study of 1508 patients with
severe AKI found that only 5.4% of survivors still required
renal replacement therapy by day 90.21 Finally, there is
emerging evidence showing that less severe AKI may be
associated with important long-term outcomes including
progression of CKD and cardiovascular disease.22
Unfortunately, very little is known about why AKI is
associated with short- and long-term adverse affects.
Although some manifestations of AKI are directly linked to
impaired glomerular/tubular function and easily recognized
at the bedside in the form of hyperkalemia, pulmonary
edema, pericarditis, or encephalopathy, other effects are less
obvious or might not become apparent until sometime after
the patient has left the hospital. Here, the modulatory effects
of AKI on the (innate) immune system and the progression
from AKI to CKD have recently emerged as very critical and
highly important factors.
AKI and the (innate) immune system
Current concepts about the effects of AKI on the innate
immune system largely stem from experimental studies and
mostly focus on interactions between the kidneys and remote
organs, such as the lungs and heart. Experimental AKI has
some striking effects on the heart.23 Bilateral renal ischemia
significantly increases the myocardial transcription of tumor
necrosis factor-a and interleukin (IL)-1. These transcriptional
changes are associated with an increase in myocardial neutro-
phil recruitment, as evidenced by elevated myeloperoxidase
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activity, and myocardial apoptosis. Blockade of tumor necrosis
factor-a inhibited apoptosis. Moreover, renal ischemia–reper-
fusion also led to increases in left ventricular end-diastolic
diameter and left ventricular end-systolic diameter, while
decreasing fractional shortening.
Several studies have shown that bilateral ischemic AKI
induces proinflammatory changes in the uninjured lung. In
particular, post-ischemic AKI downregulates the pulmonary
expression of epithelial sodium channels, Na/K–ATPase, and
aquaporin-5.24 The observed parallel increase in lung
permeability is presumably a consequence of these changes,
as all of these proteins have important roles in transepithelial
salt and water transport and consequently in alveolar
permeability.25–27 In various experimental models, AKI also
leads to altered pulmonary cytokine expression and to
changes in serum cytokine concentrations. This includes
changes in IL-1, IL-6, IL-12, granulocyte-macrophage
colony-stimulating factor, and IL-10, as well as in some
neutrophil-specific chemokines.28 However, not all mediators
are upregulated in all animal models at the same time.
Different models of AKI or acute loss of renal function reveal
a similar, but unique, cytokine/chemokine profile.29 For
example, only mild increases in plasma IL-6 occurred in a
mouse model of folic acid-induced AKI.30 Prophylactic
administration of anti-inflammatory agents, such as IL-10
or antibodies against IL-6, can attenuate the inflammatory
response and subsequent lung damage after bilateral
nephrectomy or renal ischemia.28,31
Although the effects of AKI on the healthy lung appear to
be largely pro-inflammatory, there is sound experimental
evidence that AKI exerts anti-inflammatory effects on the
injured lung. In a neutrophil-dependent model of HCl-
induced acute lung injury, AKI impaired neutrophil recruit-
ment into the lungs and thereby improved oxygenation.32
The anti-inflammatory effects of AKI seemed to largely rest
with neutrophils, as only circulating uremic neutrophils but
not normal neutrophils circulating in uremic plasma
provided protection from acute lung injury. Moreover, the
anti-inflammatory effects of AKI appeared to outweigh the
potential effects of impaired fluid balance, as the wet–dry
ratios of HCl-injured lungs were not affected, at least early
on, by AKI. These findings are supported by a recent study
combining AKI with the ventilator-induced lung injury.33
Here, the authors found that post-ischemic AKI in the
context of ventilator-induced acute lung injury decreased
protein concentrations and neutrophil counts in bronchoal-
veolar lavage fluid. Although the anti-inflammatory effects of
AKI appear to be beneficial in the setting of sterile lung
injury, these findings certainly raise concerns for the
combined occurrence of AKI and bacterial infections, such
as pneumonia. We have shown in animal studies combining
two different models of AKI with Pseudomonas aeruginosa
K+
H+
HCO3–
Acute kidney injury
Fluid
overload
Electrolyte/acid–base
abnormalities
Impaired innate
immunity
Chronic kidney
disease
Figure 2 |Acute kidney injury (AKI) can have both immediately recognizable consequences as well as less noticeable or delayed
consequences. Fluid overload and electrolyte/acid–base abnormalities represent well known, easily recognized consequences of AKI.
Contrary, impaired innate immunity and chronic kidney disease do not manifest themselves immediately.
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pneumonia that AKI significantly impairs pulmonary
recruitment of neutrophils, in particular neutrophil transmi-
gration.30 Consequently, oxygenation and bacterial load
following inhalation of P. aeruginosa were worse in mice
with AKI than in mice without it.
Moreover, we were able to show in another recent study
that patients with septic AKI have impaired leukocyte rolling
when compared with septic patients without AKI.34 The
findings that AKI affects neutrophil recruitment and subse-
quently causes higher bacterial load and worse outcome are
further supported by clinical observations. Compared with
patients without AKI, patients with AKI more frequently
demonstrate bacteremia and poor outcome in various clinical
settings, including peritonitis, after cardiac surgery and
during hematological malignancies.35–37
AKI and CKD
Several recent clinical studies have provided evidence for a
link between AKI, CKD, and ultimately progression to end-
stage renal disease.22,38–48 Under normal circumstances, the
regeneration of the tubular epithelium after AKI occurs in a
cascade-like manner, including initial de-differentiation,
migration, proliferation of surviving cells, re-differentiation,
and, in a last step, the full restoration of the tubular
epithelium. Incomplete repair after AKI, by contrast, is
characterized by persistent tubulointerstitial fibrosis and
inflammation, even in the absence of prior kidney dis-
ease.49,50 Persistent tubular interstitial fibrosis is the patho-
logical correlate of loss of kidney function. The severity of
AKI significantly determines the extent of recovery.50,51
It is well accepted that preexisting kidney disease increases
a patient’s risk of developing AKI; the risk for AKI is
proportional to the respective CKD stage.40,42,43,45 On the
other hand, any episode of AKI in a patient with underlying
CKD inflicts additional damage on already compromised
kidneys and thereby substantially increases the rate of
transition to end-stage renal disease.39,42,43,45 Progressive
kidney disease is more likely after an episode of acute-on-
chronic kidney injury than after simple AKI alone.43
As much as inflammation is crucial for the development
of AKI, it also has a crucial role in the development of
interstitial fibrosis after AKI. Experimental studies have
shown a delayed mononuclear cell infiltration after AKI,
which is a central factor in kidney repair, regeneration, and
tissue remodeling.52,53 Although monocytes aggravate tissue
injury after ischemia–reperfusion, they also contribute to
fibroblast proliferation and tubular interstitial fibrosis.
Capillary rarefaction represents another hallmark of tubular
interstitial fibrosis.54,55 Regeneration after AKI includes rapid
and intense activation of different signaling pathways in
tubular epithelial cells, giving rise to the production and
secretion of growth factors, cytokines, and other mediators.
Among the receptors and their respective pathways involved
are Toll-like receptors, receptor tyrosine kinases, G-protein-
coupled receptors, and peroxisome proliferator-activated
receptor. They are thought to participate through the nuclear
factor-kB-, phosphatidylinositol 3-kinase-, mitogen-activated
protein kinase-, and Smad-dependent pathways.56–64 Activa-
tion of these pathways in turn leads to enhanced production
of numerous mediators that are involved in repair, regenera-
tion, and remodeling of the kidney, such as platelet-derived
growth factor, transforming growth factor, colony-stimulat-
ing factor, and epidermal growth factor.65,66 Many of the
secreted molecules have both autocrine and paracrine
functions. They recruit and mobilize leukocytes and also
stimulate endothelial cells and fibroblasts. All injured and
regenerating tubular cells, endothelial cells, interstitial cells,
and recruited inflammatory cells can produce and release
these substances.65,66
CONCLUSION
Over the past few years, both experimental and clinical
research has made important changes to the way AKI and its
impact on morbidity/mortality are perceived. The develop-
ment of AKI is the consequence of complex interactions
between the actual insult and subsequent activation of
inflammation and coagulation. Contrary to the conventional
view, recent experimental and clinical data argue against
renal ischemia (and reperfusion) as a sine qua non condition
for the development of AKI. Moreover, loss of renal function
can occur without histological signs of tubular damage or
even necrosis.
It has become very clear that patients, especially patients
in the ICU, are dying of AKI and not just simply with AKI.
Even small changes in serum creatinine concentrations are
associated with a substantial increase in the risk of death.
Moreover, the detrimental effects of AKI are not limited to
classical well-known symptoms such as fluid overload and
electrolyte abnormalities. AKI can also cause problems that
are not readily appreciated at the bedside and can extend well
beyond ICU stay. Experimental and small observational
studies provide evidence that AKI negatively affects (innate)
immunity and is associated with higher rates of infection.
Furthermore, AKI can also serve as a springboard for the
development of CKD, in particular in patients with under-
lying renal insufficiency.
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